PREVENTING THE INDUCTION OF FATTY ACID OXIDATION IN RESPONSE TO S6K1 INACTIVATION

TECHNICAL FIELD
Therapeutic

APPLICATION
Combining antagonists of fatty acid oxidation mediators with Rapamycin

DESCRIPTION
Dr. David Plas has identified a new method that enhances cancer cell cytotoxicity when used in combination with Rapamycin.

Although Rapamycin suppresses glycolysis in cancer cells, the cytotoxic benefit of Rapamycin is unexpectedly low in many cancers. Agents that inhibit fatty acid oxidation in tumor cells can compensate for this shortcoming by blocking a key metabolic pathway that cancer cells use to survive during Rapamycin therapy.

ADVANTAGE
Increases cancer cell cytotoxicity compared with the use of Rapamycin alone

INVENTORS
Dr. David R. Plas, PhD
Assistant Professor
Cancer and Cell Biology

STATUS
Patent Application Filed

CONTACT
Lynn Briggs
Licensing Associate
lynn.briggs@uc.edu
513-558-3098